Background: Dalbavancin (DAL) may obviate concerns regarding misuse of IV access in persons who use drugs (PWUD) completing treatment for infections in an outpatient setting. However, hesitancy to adopt its use exists due to the cost-prohibitive nature of DAL and perceived issues with insurance reimbursement. Our study looks to determine the financial impact of DAL use in actual, measured cost, and health care utilization, data as well as the effect on treatment completion rates. Methods: This is a retrospective cohort comparing cost information and treatment completion rates of patients who received DAL to a random sample of patients with Staphylococcus aureus bacteremia prior to the institutional availability of DAL. Results: From June 2020 to January 2022, 29 PWUD received DAL. Dalbavancin use resulted in the completion of intended duration in 19 patients (66%) compared with 11 (55%) without DAL. The contribution margin with DAL use was $7180 compared with $6655 without; this was not statistically significant (P = 0.47). Conclusion: Dalbavancin use in PWUD may increase treatment completion, with no statistically significant difference in contribution margins.
展开▼
机译：背景：达巴万星 （DAL） 可以消除对在门诊完成感染治疗的药物使用者 （PWUD） 滥用 IV 通路的担忧。然而，由于 DAL 的成本高昂的性质和认为保险报销存在问题，因此对采用其使用存在犹豫。我们的研究旨在确定 DAL 使用在实际、测量成本和医疗保健利用率、数据中的财务影响，以及对治疗完成率的影响。方法：这是一个回顾性队列，将接受 DAL 的患者的成本信息和治疗完成率与 DAL 机构可用性之前的金黄色葡萄球菌菌血症患者的随机样本进行比较。结果： 从 2020 年 6 月到 2022 年 1 月，有 29 名 PWUD 获得了 DAL。达巴万星的使用导致 19 名患者 （66%） 完成了预期持续时间，而没有 DAL 的患者有 11 名 （55%） 完成。使用 DAL 的边际贡献为 7180 美元，而没有 DAL 的贡献为 6655 美元;这没有统计学意义 （P = 0.47）。结论： 在 PWUD 中使用达巴万星可能会增加治疗完成率，边际贡献没有统计学意义差异。
展开▼
